Bipolar Research Today is a free monthly online journal that collates and summarizes the latest research about Bipolar, including details on bipolar disorder, symptoms, treatment, depression, medication.

Volume 7 (2010), Issue 12 (December)

1. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.
   J Psychiatry Neurosci, 35(6): 100057. [Abstract] [Full-text]
2. Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder.
   Australas Psychiatry, 18(6): 556-9. [Abstract] [Full-text]
3. Why do adolescents return to an acute psychiatric unit?
   Australas Psychiatry, 18(6): 551-5. [Abstract] [Full-text]
4. The role of fragile X mental retardation protein in major mental disorders.
   Neuropharmacology. [Abstract] [Full-text]
5. A genetic network model of cellular responses to lithium treatment and cocaine abuse in bipolar disorder.
   BMC Syst Biol, 4: 158. [Abstract] [Full-text]
6. Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder.
   Australas Psychiatry, 18(6): 556-9. [Abstract] [Full-text]
7. Why do adolescents return to an acute psychiatric unit?
   Australas Psychiatry, 18(6): 551-5. [Abstract] [Full-text]
8. The role of fragile X mental retardation protein in major mental disorders.
   Neuropharmacology. [Abstract] [Full-text]
9. A genetic network model of cellular responses to lithium treatment and cocaine abuse in bipolar disorder.
   BMC Syst Biol, 4: 158. [Abstract] [Full-text]
10. Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder.
    Australas Psychiatry, 18(6): 556-9. [Abstract] [Full-text]
11. Why do adolescents return to an acute psychiatric unit?
    Australas Psychiatry, 18(6): 551-5. [Abstract] [Full-text]
12. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.
    Int J Neuropsychopharmacol, 14(1): 131-42. [Abstract] [Full-text]
13. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders.
    Int J Neuropsychopharmacol, 14(1): 123-30. [Abstract] [Full-text]
14. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.
    Int J Neuropsychopharmacol, 14(1): 131-42. [Abstract] [Full-text]
15. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders.
    Int J Neuropsychopharmacol, 14(1): 123-30. [Abstract] [Full-text]
16. Lithium ameliorates nucleus accumbens phase-signaling dysfunction in a genetic mouse model of mania.
    J Neurosci, 30(48): 16314-23. [Abstract] [Full-text]
17. Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths.
    Am J Psychiatry. [Abstract] [Full-text]
18. Valproate induces DNA demethylation in nuclear extracts from adult mouse brain.
    Epigenetics, 5(8): 730-5. [Abstract] [Full-text]
19. Stereotactic lesions for the treatment of psychiatric disorders.
    J Neurosurg, 113(6): 1204-11. [Abstract] [Full-text]
20. Thalamic volumes in patients with bipolar disorder.
    Eur Arch Psychiatry Clin Neurosci, 260(8): 601-7. [Abstract] [Full-text]
21. Lithium ameliorates nucleus accumbens phase-signaling dysfunction in a genetic mouse model of mania.
    J Neurosci, 30(48): 16314-23. [Abstract] [Full-text]
22. Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths.
    Am J Psychiatry. [Abstract] [Full-text]
23. Stereotactic lesions for the treatment of psychiatric disorders.
    J Neurosurg, 113(6): 1204-11. [Abstract] [Full-text]
24. Thalamic volumes in patients with bipolar disorder.
    Eur Arch Psychiatry Clin Neurosci, 260(8): 601-7. [Abstract] [Full-text]
25. Lithium ameliorates nucleus accumbens phase-signaling dysfunction in a genetic mouse model of mania.
    J Neurosci, 30(48): 16314-23. [Abstract] [Full-text]
26. Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths.
    Am J Psychiatry. [Abstract] [Full-text]
27. Stereotactic lesions for the treatment of psychiatric disorders.
    J Neurosurg, 113(6): 1204-11. [Abstract] [Full-text]
28. Thalamic volumes in patients with bipolar disorder.
    Eur Arch Psychiatry Clin Neurosci, 260(8): 601-7. [Abstract] [Full-text]
29. Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.
    Neuropsychiatr Dis Treat, 6: 749-66. [Abstract] [Full-text]
30. Obsessive-compulsive disorder with bipolar diathesis following isotretinoin therapy remitting upon treatment with olanzapine and fluvoxamine.
    Neuropsychiatr Dis Treat, 6: 719-22. [Abstract] [Full-text]
31. Impulsivity and aggressiveness in bipolar disorder with co-morbid borderline personality disorder.
    Psychiatry Res. [Abstract] [Full-text]
32. An admixture analysis of the age at index episodes in bipolar disorder.
    Psychiatry Res. [Abstract] [Full-text]
33. A systematic review of the global distribution and availability of prevalence data for bipolar disorder.
    J Affect Disord. [Abstract] [Full-text]
34. Atypical antipsychotic medications in the management of disruptive behaviors in children: Safety guidelines and recommendations.
    Clin Psychol Rev. [Abstract] [Full-text]
35. Association of DRD2 gene polymorphisms with mood disorders: A meta-analysis.
    J Affect Disord. [Abstract] [Full-text]
36. Evaluating the first 1000 patients referred to a specialist depression clinic: A case for tertiary referral facilities.
    J Affect Disord. [Abstract] [Full-text]
37. Sexual behavior in women with bipolar disorder.
    J Affect Disord. [Abstract] [Full-text]
38. Genome-wide association study of suicide attempts in mood disorder patients.
    Am J Psychiatry, 167(12): 1499-507. [Abstract] [Full-text]
39. Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease.
    Parkinsonism Relat Disord, 16(10): 686-7. [Abstract] [Full-text]
40. Impulsivity and aggressiveness in bipolar disorder with co-morbid borderline personality disorder.
    Psychiatry Res. [Abstract] [Full-text]
41. An admixture analysis of the age at index episodes in bipolar disorder.
    Psychiatry Res. [Abstract] [Full-text]
42. A systematic review of the global distribution and availability of prevalence data for bipolar disorder.
    J Affect Disord. [Abstract] [Full-text]
43. Atypical antipsychotic medications in the management of disruptive behaviors in children: Safety guidelines and recommendations.
    Clin Psychol Rev. [Abstract] [Full-text]
44. Association of DRD2 gene polymorphisms with mood disorders: A meta-analysis.
    J Affect Disord. [Abstract] [Full-text]
45. Evaluating the first 1000 patients referred to a specialist depression clinic: A case for tertiary referral facilities.
    J Affect Disord. [Abstract] [Full-text]
46. Sexual behavior in women with bipolar disorder.
    J Affect Disord. [Abstract] [Full-text]
47. Genome-wide association study of suicide attempts in mood disorder patients.
    Am J Psychiatry, 167(12): 1499-507. [Abstract] [Full-text]
48. Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease.
    Parkinsonism Relat Disord, 16(10): 686-7. [Abstract] [Full-text]
49. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence.
    Psychol Med, 41(1): 33-40. [Abstract] [Full-text]
50. Regaining mental capacity for treatment decisions following psychiatric admission: a clinico-ethical study.
    Psychol Med, 41(1): 119-28. [Abstract] [Full-text]
51. Impulsivity and aggressiveness in bipolar disorder with co-morbid borderline personality disorder.
    Psychiatry Res. [Abstract] [Full-text]
52. An admixture analysis of the age at index episodes in bipolar disorder.
    Psychiatry Res. [Abstract] [Full-text]
53. A systematic review of the global distribution and availability of prevalence data for bipolar disorder.
    J Affect Disord. [Abstract] [Full-text]
54. Association of DRD2 gene polymorphisms with mood disorders: A meta-analysis.
    J Affect Disord. [Abstract] [Full-text]
55. Evaluating the first 1000 patients referred to a specialist depression clinic: A case for tertiary referral facilities.
    J Affect Disord. [Abstract] [Full-text]
56. Sexual behavior in women with bipolar disorder.
    J Affect Disord. [Abstract] [Full-text]
57. Genome-wide association study of suicide attempts in mood disorder patients.
    Am J Psychiatry, 167(12): 1499-507. [Abstract] [Full-text]
58. Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease.
    Parkinsonism Relat Disord, 16(10): 686-7. [Abstract] [Full-text]
59. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence.
    Psychol Med, 41(1): 33-40. [Abstract] [Full-text]
60. Regaining mental capacity for treatment decisions following psychiatric admission: a clinico-ethical study.
    Psychol Med, 41(1): 119-28. [Abstract] [Full-text]
61. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence.
    Psychol Med, 41(1): 33-40. [Abstract] [Full-text]
62. Regaining mental capacity for treatment decisions following psychiatric admission: a clinico-ethical study.
    Psychol Med, 41(1): 119-28. [Abstract] [Full-text]
63. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence.
    Psychol Med, 41(1): 33-40. [Abstract] [Full-text]
64. Regaining mental capacity for treatment decisions following psychiatric admission: a clinico-ethical study.
    Psychol Med, 41(1): 119-28. [Abstract] [Full-text]
65. Hippocampal Interneurons in Bipolar Disorder.
    Arch Gen Psychiatry. [Abstract] [Full-text]
66. Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder.
    Arch Gen Psychiatry. [Abstract] [Full-text]
67. Psychotropic Drug-Related Eosinophilia With Systemic Symptoms After Acute Caffeine Ingestion.
    Pediatrics. [Abstract] [Full-text]
68. Personality and bipolar disorder: dissecting state and trait associations between mood and personality.
    Psychol Med. [Abstract] [Full-text]
69. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?
    Acta Psychiatr Scand. [Abstract] [Full-text]
70. Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function.
    Biomark Med, 4(6): 871-87. [Abstract] [Full-text]
71. Volume reduction of ventromedial prefrontal cortex in bipolar II patients with rapid cycling: A voxel-based morphometric study.
    Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
72. Hippocampal Interneurons in Bipolar Disorder.
    Arch Gen Psychiatry. [Abstract] [Full-text]
73. Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder.
    Arch Gen Psychiatry. [Abstract] [Full-text]
74. Psychotropic Drug-Related Eosinophilia With Systemic Symptoms After Acute Caffeine Ingestion.
    Pediatrics. [Abstract] [Full-text]
75. Personality and bipolar disorder: dissecting state and trait associations between mood and personality.
    Psychol Med. [Abstract] [Full-text]
76. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?
    Acta Psychiatr Scand. [Abstract] [Full-text]
77. Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function.
    Biomark Med, 4(6): 871-87. [Abstract] [Full-text]
78. Hippocampal Interneurons in Bipolar Disorder.
    Arch Gen Psychiatry. [Abstract] [Full-text]
79. Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder.
    Arch Gen Psychiatry. [Abstract] [Full-text]
80. Personality and bipolar disorder: dissecting state and trait associations between mood and personality.
    Psychol Med. [Abstract] [Full-text]
81. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?
    Acta Psychiatr Scand. [Abstract] [Full-text]
82. Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function.
    Biomark Med, 4(6): 871-87. [Abstract] [Full-text]
83. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder.
    J Psychiatry Neurosci, 35(6): 100080. [Abstract] [Full-text]
84. Increased breath ethane levels in medicated patients with schizophrenia and bipolar disorder are unrelated to erythrocyte omega-3 fatty acid abundance.
    Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
85. Brain metabolite concentrations across cortical regions in healthy adults.
    Brain Res. [Abstract] [Full-text]
86. Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid population.
    J Med Econ, 13(4): 698-704. [Abstract] [Full-text]
87. Functional Impairment and Disability across Mood States in Bipolar Disorder.
    Value Health, 13(8): 984-8. [Abstract] [Full-text]
88. Lithium in bipolar and other affective disorders: prescribing practice in the UK.
    J Psychopharmacol, 24(12): 1739-46. [Abstract] [Full-text]
89. Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance.
    J Psychopharmacol, 24(12): 1747-54. [Abstract] [Full-text]
90. The long-term effectiveness of clozapine and lamotrigine in a patient with treatment-resistant rapid-cycling bipolar disorder.
    J Psychopharmacol, 24(12): 1834-6. [Abstract] [Full-text]
91. The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: role of brain-derived neurotrophic factor.
    J Psychopharmacol, 24(12): 1772-8. [Abstract] [Full-text]
92. Perturbed reward processing in pediatric bipolar disorder: an antisaccade study.
    J Psychopharmacol, 24(12): 1779-84. [Abstract] [Full-text]
93. Olanzapine in the long-term treatment of bipolar disorder: A systematic review and meta-analysis.
    J Psychopharmacol, 24(12): 1729-38. [Abstract] [Full-text]
94. Brain metabolite concentrations across cortical regions in healthy adults.
    Brain Res. [Abstract] [Full-text]
95. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance.
    Int Clin Psychopharmacol, 26(1): 48-53. [Abstract] [Full-text]
96. Functional impairment and disability across mood states in bipolar disorder.
    Value Health, 13(8): 984-8. [Abstract] [Full-text]
97. Lithium in bipolar and other affective disorders: prescribing practice in the UK.
    J Psychopharmacol, 24(12): 1739-46. [Abstract] [Full-text]
98. Patterns of psychiatric and physical comorbidities associated with panic disorder in a nationwide population-based study in Taiwan.
    Acta Psychiatr Scand, 123(1): 55-61. [Abstract] [Full-text]
99. Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance.
    J Psychopharmacol, 24(12): 1747-54. [Abstract] [Full-text]
100. The long-term effectiveness of clozapine and lamotrigine in a patient with treatment-resistant rapid-cycling bipolar disorder.
     J Psychopharmacol, 24(12): 1834-6. [Abstract] [Full-text]
101. The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: role of brain-derived neurotrophic factor.
     J Psychopharmacol, 24(12): 1772-8. [Abstract] [Full-text]
102. Perturbed reward processing in pediatric bipolar disorder: an antisaccade study.
     J Psychopharmacol, 24(12): 1779-84. [Abstract] [Full-text]
103. Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis.
     J Psychopharmacol, 24(12): 1729-38. [Abstract] [Full-text]
104. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance.
     Int Clin Psychopharmacol, 26(1): 48-53. [Abstract] [Full-text]
105. Functional impairment and disability across mood states in bipolar disorder.
     Value Health, 13(8): 984-8. [Abstract] [Full-text]
106. Lithium in bipolar and other affective disorders: prescribing practice in the UK.
     J Psychopharmacol, 24(12): 1739-46. [Abstract] [Full-text]
107. Patterns of psychiatric and physical comorbidities associated with panic disorder in a nationwide population-based study in Taiwan.
     Acta Psychiatr Scand, 123(1): 55-61. [Abstract] [Full-text]
108. Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance.
     J Psychopharmacol, 24(12): 1747-54. [Abstract] [Full-text]
109. The long-term effectiveness of clozapine and lamotrigine in a patient with treatment-resistant rapid-cycling bipolar disorder.
     J Psychopharmacol, 24(12): 1834-6. [Abstract] [Full-text]
110. The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: role of brain-derived neurotrophic factor.
     J Psychopharmacol, 24(12): 1772-8. [Abstract] [Full-text]
111. Perturbed reward processing in pediatric bipolar disorder: an antisaccade study.
     J Psychopharmacol, 24(12): 1779-84. [Abstract] [Full-text]
112. Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis.
     J Psychopharmacol, 24(12): 1729-38. [Abstract] [Full-text]
113. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance.
     Int Clin Psychopharmacol, 26(1): 48-53. [Abstract] [Full-text]
114. Patterns of psychiatric and physical comorbidities associated with panic disorder in a nationwide population-based study in Taiwan.
     Acta Psychiatr Scand, 123(1): 55-61. [Abstract] [Full-text]
115. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance.
     Int Clin Psychopharmacol, 26(1): 48-53. [Abstract] [Full-text]
116. Patterns of psychiatric and physical comorbidities associated with panic disorder in a nationwide population-based study in Taiwan.
     Acta Psychiatr Scand, 123(1): 55-61. [Abstract] [Full-text]
117. Psychopathology and intellectual disability.
     Curr Opin Psychiatry. [Abstract] [Full-text]
118. The MDGA1 gene confers risk to schizophrenia and bipolar disorder.
     Schizophr Res. [Abstract] [Full-text]
119. Effect of comorbid alcohol and drug use disorders on premature death among unipolar and bipolar disorder decedents in the United States, 1999 to 2006.
     Compr Psychiatry. [Abstract] [Full-text]
120. A French network of bipolar expert centres: A model to close the gap between evidence-based medicine and routine practice.
     J Affect Disord. [Abstract] [Full-text]
121. Is the Mood Disorder Questionnaire an appropriate screening tool in detecting bipolar spectrum disorder among substance use populations?
     Am J Drug Alcohol Abuse. [Abstract] [Full-text]
122. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival.
     Proteomics. [Abstract] [Full-text]
123. Between destiny and disease: Genetics and molecular pathways of human central nervous system aging.
     Prog Neurobiol. [Abstract] [Full-text]
124. A pilot study of antipsychotic prescribing decisions for acutely-Ill hospitalized patients.
     Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
125. Molecular pharmacology in a simple model system: Implicating MAP kinase and phosphoinositide signalling in bipolar disorder.
     Semin Cell Dev Biol. [Abstract] [Full-text]
126. The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes.
     Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
127. Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials.
     Neuropsychopharmacology, 36(2): 375-89. [Abstract] [Full-text]
128. The impact of premenstrual dysphoric disorder among 92 bipolar patients.
     Eur Psychiatry, 25(8): 450-4. [Abstract] [Full-text]
129. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005.
     Eur Psychiatry, 25(8): 443-9. [Abstract] [Full-text]
130. Psychopathology and intellectual disability.
     Curr Opin Psychiatry. [Abstract] [Full-text]
131. The MDGA1 gene confers risk to schizophrenia and bipolar disorder.
     Schizophr Res. [Abstract] [Full-text]
132. Effect of comorbid alcohol and drug use disorders on premature death among unipolar and bipolar disorder decedents in the United States, 1999 to 2006.
     Compr Psychiatry. [Abstract] [Full-text]
133. A French network of bipolar expert centres: A model to close the gap between evidence-based medicine and routine practice.
     J Affect Disord. [Abstract] [Full-text]
134. Is the Mood Disorder Questionnaire an appropriate screening tool in detecting bipolar spectrum disorder among substance use populations?
     Am J Drug Alcohol Abuse. [Abstract] [Full-text]
135. Between destiny and disease: Genetics and molecular pathways of human central nervous system aging.
     Prog Neurobiol. [Abstract] [Full-text]
136. A pilot study of antipsychotic prescribing decisions for acutely-Ill hospitalized patients.
     Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
137. Molecular pharmacology in a simple model system: Implicating MAP kinase and phosphoinositide signalling in bipolar disorder.
     Semin Cell Dev Biol. [Abstract] [Full-text]
138. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials.
     Neuropsychopharmacology, 36(2): 375-89. [Abstract] [Full-text]
139. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.
     Neurosci Biobehav Rev, 35(3): 804-17. [Abstract] [Full-text]
140. The impact of premenstrual dysphoric disorder among 92 bipolar patients.
     Eur Psychiatry, 25(8): 450-4. [Abstract] [Full-text]
141. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005.
     Eur Psychiatry, 25(8): 443-9. [Abstract] [Full-text]
142. Psychopathology and intellectual disability.
     Curr Opin Psychiatry. [Abstract] [Full-text]
143. The MDGA1 gene confers risk to schizophrenia and bipolar disorder.
     Schizophr Res. [Abstract] [Full-text]
144. Effect of comorbid alcohol and drug use disorders on premature death among unipolar and bipolar disorder decedents in the United States, 1999 to 2006.
     Compr Psychiatry. [Abstract] [Full-text]
145. A French network of bipolar expert centres: A model to close the gap between evidence-based medicine and routine practice.
     J Affect Disord. [Abstract] [Full-text]
146. Is the Mood Disorder Questionnaire an appropriate screening tool in detecting bipolar spectrum disorder among substance use populations?
     Am J Drug Alcohol Abuse. [Abstract] [Full-text]
147. Between destiny and disease: Genetics and molecular pathways of human central nervous system aging.
     Prog Neurobiol. [Abstract] [Full-text]
148. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials.
     Neuropsychopharmacology, 36(2): 375-89. [Abstract] [Full-text]
149. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.
     Neurosci Biobehav Rev, 35(3): 804-17. [Abstract] [Full-text]
150. The impact of premenstrual dysphoric disorder among 92 bipolar patients.
     Eur Psychiatry, 25(8): 450-4. [Abstract] [Full-text]
151. In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005.
     Eur Psychiatry, 25(8): 443-9. [Abstract] [Full-text]
152. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials.
     Neuropsychopharmacology, 36(2): 375-89. [Abstract] [Full-text]
153. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.
     Neurosci Biobehav Rev, 35(3): 804-17. [Abstract] [Full-text]
154. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials.
     Neuropsychopharmacology, 36(2): 375-89. [Abstract] [Full-text]
155. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.
     Neurosci Biobehav Rev, 35(3): 804-17. [Abstract] [Full-text]
156. Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a (1)h magnetic resonance spectroscopy study.
     J Am Acad Child Adolesc Psychiatry, 50(1): 85-94. [Abstract] [Full-text]
157. Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a ¹H magnetic resonance spectroscopy study.
     J Am Acad Child Adolesc Psychiatry, 50(1): 85-94. [Abstract] [Full-text]
158. Genetic variation in G72 correlates with brain activation in the right middle temporal gyrus in a verbal fluency task in healthy individuals.
     Hum Brain Mapp, 32(1): 118-26. [Abstract] [Full-text]
159. Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a ¹H magnetic resonance spectroscopy study.
     J Am Acad Child Adolesc Psychiatry, 50(1): 85-94. [Abstract] [Full-text]
160. Genetic variation in G72 correlates with brain activation in the right middle temporal gyrus in a verbal fluency task in healthy individuals.
     Hum Brain Mapp, 32(1): 118-26. [Abstract] [Full-text]
161. Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a ¹H magnetic resonance spectroscopy study.
     J Am Acad Child Adolesc Psychiatry, 50(1): 85-94. [Abstract] [Full-text]
162. Genetic variation in G72 correlates with brain activation in the right middle temporal gyrus in a verbal fluency task in healthy individuals.
     Hum Brain Mapp, 32(1): 118-26. [Abstract] [Full-text]
163. Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a ¹H magnetic resonance spectroscopy study.
     J Am Acad Child Adolesc Psychiatry, 50(1): 85-94. [Abstract] [Full-text]
164. Genetic variation in G72 correlates with brain activation in the right middle temporal gyrus in a verbal fluency task in healthy individuals.
     Hum Brain Mapp, 32(1): 118-26. [Abstract] [Full-text]
165. Informing the symptom profile of complicated grief.
     Depress Anxiety. [Abstract] [Full-text]
166. Modulation of human motor cortex excitability by valproate.
     Psychopharmacology (Berl). [Abstract] [Full-text]
167. Tolerance to the Prophylactic Effects of Carbamazepine and Related Mood Stabilizers in the Treatment of Bipolar Disorders.
     CNS Neurosci Ther. [Abstract] [Full-text]
168. A comparison of depressed patients with and without borderline personality disorder: implications for interpreting studies of the validity of the bipolar spectrum.
     J Pers Disord, 24(6): 763-72. [Abstract] [Full-text]
169. No association of Disrupted-in-Schizophrenia-1 variation with prefrontal function in patients with schizophrenia and bipolar disorder.
     Genes Brain Behav. [Abstract] [Full-text]
170. Informing the symptom profile of complicated grief.
     Depress Anxiety. [Abstract] [Full-text]
171. Modulation of human motor cortex excitability by valproate.
     Psychopharmacology (Berl). [Abstract] [Full-text]
172. Tolerance to the Prophylactic Effects of Carbamazepine and Related Mood Stabilizers in the Treatment of Bipolar Disorders.
     CNS Neurosci Ther. [Abstract] [Full-text]
173. A comparison of depressed patients with and without borderline personality disorder: implications for interpreting studies of the validity of the bipolar spectrum.
     J Pers Disord, 24(6): 763-72. [Abstract] [Full-text]
174. Mood stabilizers for patients with bipolar disorder: the state of the art.
     Expert Rev Neurother, 11(1): 85-99. [Abstract] [Full-text]
175. No association of Disrupted-in-Schizophrenia-1 variation with prefrontal function in patients with schizophrenia and bipolar disorder.
     Genes Brain Behav. [Abstract] [Full-text]
176. Informing the symptom profile of complicated grief.
     Depress Anxiety. [Abstract] [Full-text]
177. Modulation of human motor cortex excitability by valproate.
     Psychopharmacology (Berl). [Abstract] [Full-text]
178. Tolerance to the Prophylactic Effects of Carbamazepine and Related Mood Stabilizers in the Treatment of Bipolar Disorders.
     CNS Neurosci Ther. [Abstract] [Full-text]
179. A comparison of depressed patients with and without borderline personality disorder: implications for interpreting studies of the validity of the bipolar spectrum.
     J Pers Disord, 24(6): 763-72. [Abstract] [Full-text]
180. Mood stabilizers for patients with bipolar disorder: the state of the art.
     Expert Rev Neurother, 11(1): 85-99. [Abstract] [Full-text]
181. Modulation of human motor cortex excitability by valproate.
     Psychopharmacology (Berl). [Abstract] [Full-text]
182. Tolerance to the Prophylactic Effects of Carbamazepine and Related Mood Stabilizers in the Treatment of Bipolar Disorders.
     CNS Neurosci Ther. [Abstract] [Full-text]
183. Mood stabilizers for patients with bipolar disorder: the state of the art.
     Expert Rev Neurother, 11(1): 85-99. [Abstract] [Full-text]
184. Mood stabilizers for patients with bipolar disorder: the state of the art.
     Expert Rev Neurother, 11(1): 85-99. [Abstract] [Full-text]
185. Mood Disorders and Obesity: Understanding Inflammation as a Pathophysiological Nexus.
     Neuromolecular Med. [Abstract] [Full-text]
186. Assessment of Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form responder thresholds in generalized anxiety disorder and bipolar disorder studies.
     Int Clin Psychopharmacol. [Abstract] [Full-text]
187. Mood Disorders and Obesity: Understanding Inflammation as a Pathophysiological Nexus.
     Neuromolecular Med. [Abstract] [Full-text]
188. Assessment of Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form responder thresholds in generalized anxiety disorder and bipolar disorder studies.
     Int Clin Psychopharmacol. [Abstract] [Full-text]
189. Mood Disorders and Obesity: Understanding Inflammation as a Pathophysiological Nexus.
     Neuromolecular Med. [Abstract] [Full-text]
190. The ins and outs of an online bipolar education program: a study of program attrition.
     J Med Internet Res, 12(5): e57. [Abstract] [Full-text]
191. Aggression, ADHD symptoms, and dysphoria in children and adolescents diagnosed with bipolar disorder and ADHD.
     J Affect Disord. [Abstract] [Full-text]
192. Is cognitive enhancement therapy equally effective for patients with schizophrenia and schizoaffective disorder?
     Schizophr Res. [Abstract] [Full-text]
193. The role of BDNF genetic polymorphisms in bipolar disorder with psychiatric comorbidities.
     J Affect Disord. [Abstract] [Full-text]
194. The Bcl-2 Gene Polymorphism rs956572AA Increases Inositol 1,4,5-Trisphosphate Receptor-Mediated Endoplasmic Reticulum Calcium Release in Subjects with Bipolar Disorder.
     Biol Psychiatry. [Abstract] [Full-text]
195. Volume reduction of ventromedial prefrontal cortex in bipolar II patients with rapid cycling: A voxel-based morphometric study.
     Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
196. ApoE and cholesterol in schizophrenia and bipolar disorder: comparison of grey and white matter and relation with APOE genotype.
     J Psychiatry Neurosci, 36(1): 47-55. [Abstract] [Full-text]
197. Therapeutic potential of interleukin-6 antagonism in bipolar disorder.
     Med Hypotheses, 76(1): 21-3. [Abstract] [Full-text]
198. The ins and outs of an online bipolar education program: a study of program attrition.
     J Med Internet Res, 12(5): e57. [Abstract] [Full-text]
199. Aggression, ADHD symptoms, and dysphoria in children and adolescents diagnosed with bipolar disorder and ADHD.
     J Affect Disord. [Abstract] [Full-text]
200. Is cognitive enhancement therapy equally effective for patients with schizophrenia and schizoaffective disorder?
     Schizophr Res. [Abstract] [Full-text]
201. The role of BDNF genetic polymorphisms in bipolar disorder with psychiatric comorbidities.
     J Affect Disord. [Abstract] [Full-text]
202. The Bcl-2 Gene Polymorphism rs956572AA Increases Inositol 1,4,5-Trisphosphate Receptor-Mediated Endoplasmic Reticulum Calcium Release in Subjects with Bipolar Disorder.
     Biol Psychiatry. [Abstract] [Full-text]
203. ApoE and cholesterol in schizophrenia and bipolar disorder: comparison of grey and white matter and relation with APOE genotype.
     J Psychiatry Neurosci, 36(1): 47-55. [Abstract] [Full-text]
204. Therapeutic potential of interleukin-6 antagonism in bipolar disorder.
     Med Hypotheses, 76(1): 21-3. [Abstract] [Full-text]
205. The ins and outs of an online bipolar education program: a study of program attrition.
     J Med Internet Res, 12(5): e57. [Abstract] [Full-text]
206. Aggression, ADHD symptoms, and dysphoria in children and adolescents diagnosed with bipolar disorder and ADHD.
     J Affect Disord. [Abstract] [Full-text]
207. ApoE and cholesterol in schizophrenia and bipolar disorder: comparison of grey and white matter and relation with APOE genotype.
     J Psychiatry Neurosci, 36(1): 47-55. [Abstract] [Full-text]
208. Therapeutic potential of interleukin-6 antagonism in bipolar disorder.
     Med Hypotheses, 76(1): 21-3. [Abstract] [Full-text]
209. Serotonin 1A receptor gene, schizophrenia and bipolar disorder: An association study and meta-analysis.
     Psychiatry Res, 185(1): 20-6. [Abstract] [Full-text]
210. Presence of co-morbid substance use disorder in bipolar patients worsens their social functioning to the level observed in patients with schizophrenia.
     Psychiatry Res, 185(1): 129-34. [Abstract] [Full-text]
211. Admixture analysis of age at onset in bipolar disorder.
     Psychiatry Res, 185(1): 27-32. [Abstract] [Full-text]
212. Personality traits and affective morbidity in patients with bipolar I disorder: The five-factor model perspective.
     Psychiatry Res, 185(1): 135-40. [Abstract] [Full-text]
213. Positive association between GRIN2B gene and bipolar disorder in the Chinese Han Population.
     Psychiatry Res, 185(1): 290-2. [Abstract] [Full-text]
214. ApoE and cholesterol in schizophrenia and bipolar disorder: comparison of grey and white matter and relation with APOE genotype.
     J Psychiatry Neurosci, 36(1): 47-55. [Abstract] [Full-text]
215. Therapeutic potential of interleukin-6 antagonism in bipolar disorder.
     Med Hypotheses, 76(1): 21-3. [Abstract] [Full-text]
216. Serotonin 1A receptor gene, schizophrenia and bipolar disorder: an association study and meta-analysis.
     Psychiatry Res, 185(1): 20-6. [Abstract] [Full-text]
217. Presence of co-morbid substance use disorder in bipolar patients worsens their social functioning to the level observed in patients with schizophrenia.
     Psychiatry Res, 185(1): 129-34. [Abstract] [Full-text]
218. Admixture analysis of age at onset in bipolar disorder.
     Psychiatry Res, 185(1): 27-32. [Abstract] [Full-text]
219. Personality traits and affective morbidity in patients with bipolar I disorder: the five-factor model perspective.
     Psychiatry Res, 185(1): 135-40. [Abstract] [Full-text]
220. Positive association between GRIN2B gene and bipolar disorder in the Chinese Han Population.
     Psychiatry Res, 185(1): 290-2. [Abstract] [Full-text]
221. Apolipoprotein A-I as a candidate serum marker for the response to lithium treatment in bipolar disorder.
     Proteomics. [Abstract] [Full-text]
222. Preventing repetition of attempted suicide-II. The Amager Project, a randomized controlled trial.
     Nord J Psychiatry. [Abstract] [Full-text]
223. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group.
     Schizophr Bull, 37(1): 73-83. [Abstract] [Full-text]
224. Preventing repetition of attempted suicide-II. The Amager Project, a randomized controlled trial.
     Nord J Psychiatry. [Abstract] [Full-text]
225. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group.
     Schizophr Bull, 37(1): 73-83. [Abstract] [Full-text]
226. Preventing repetition of attempted suicide-II. The Amager Project, a randomized controlled trial.
     Nord J Psychiatry. [Abstract] [Full-text]
227. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group.
     Schizophr Bull, 37(1): 73-83. [Abstract] [Full-text]
228. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group.
     Schizophr Bull, 37(1): 73-83. [Abstract] [Full-text]
229. Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany.
     Int Clin Psychopharmacol. [Abstract] [Full-text]
230. Prefrontal and paralimbic metabolic dysregulation related to sustained attention in euthymic older adults with bipolar disorder.
     Bipolar Disord, 12(8): 866-74. [Abstract] [Full-text]
231. One-year post-hospital medical costs and relapse rates of bipolar disorder patients in Taiwan: a population-based study.
     Bipolar Disord, 12(8): 859-65. [Abstract] [Full-text]
232. The relationship of bipolar disorder lifetime duration and vascular burden to cognition in older adults.
     Bipolar Disord, 12(8): 851-858. [Abstract] [Full-text]
233. Social competence and observer-rated social functioning in bipolar disorder.
     Bipolar Disord, 12(8): 843-50. [Abstract] [Full-text]
234. Immune activation by casein dietary antigens in bipolar disorder.
     Bipolar Disord, 12(8): 834-42. [Abstract] [Full-text]
235. Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T.
     Bipolar Disord, 12(8): 825-33. [Abstract] [Full-text]
236. Increased peripheral blood expression of electron transport chain genes in bipolar depression.
     Bipolar Disord, 12(8): 813-24. [Abstract] [Full-text]
237. Differentiation between bipolar disorder and schizophrenia revealed by neural oscillation to speech sounds: an MEG study.
     Bipolar Disord, 12(8): 804-12. [Abstract] [Full-text]
238. Auditory steady state response in bipolar disorder: relation to clinical state, cognitive performance, medication status, and substance disorders.
     Bipolar Disord, 12(8): 793-803. [Abstract] [Full-text]
239. Family-based association analysis to finemap bipolar linkage peak on chromosome 8q24 using 2,500 genotyped SNPs and 15,000 imputed SNPs.
     Bipolar Disord, 12(8): 786-92. [Abstract] [Full-text]
240. Striatal structure and function in mood disorders: a comprehensive review.
     Bipolar Disord, 12(8): 764-85. [Abstract] [Full-text]
241. Utilization of residential alcoholism treatment in bipolar disorder.
     Am J Addict, 20(1): 40-4. [Abstract] [Full-text]
242. Impact of psychiatric comorbidity on mortality in veterans with type 2 diabetes.
     Diabetes Technol Ther, 13(1): 73-8. [Abstract] [Full-text]
243. Expanding the range of ZNF804A variants conferring risk of psychosis.
     Mol Psychiatry, 16(1): 59-66. [Abstract] [Full-text]
244. Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany.
     Int Clin Psychopharmacol. [Abstract] [Full-text]
245. Prefrontal and paralimbic metabolic dysregulation related to sustained attention in euthymic older adults with bipolar disorder.
     Bipolar Disord, 12(8): 866-74. [Abstract] [Full-text]
246. One-year post-hospital medical costs and relapse rates of bipolar disorder patients in Taiwan: a population-based study.
     Bipolar Disord, 12(8): 859-65. [Abstract] [Full-text]
247. The relationship of bipolar disorder lifetime duration and vascular burden to cognition in older adults.
     Bipolar Disord, 12(8): 851-8. [Abstract] [Full-text]
248. Social competence and observer-rated social functioning in bipolar disorder.
     Bipolar Disord, 12(8): 843-50. [Abstract] [Full-text]
249. Immune activation by casein dietary antigens in bipolar disorder.
     Bipolar Disord, 12(8): 834-42. [Abstract] [Full-text]
250. Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T.
     Bipolar Disord, 12(8): 825-33. [Abstract] [Full-text]
251. Increased peripheral blood expression of electron transport chain genes in bipolar depression.
     Bipolar Disord, 12(8): 813-24. [Abstract] [Full-text]
252. Differentiation between bipolar disorder and schizophrenia revealed by neural oscillation to speech sounds: an MEG study.
     Bipolar Disord, 12(8): 804-12. [Abstract] [Full-text]
253. Auditory steady state response in bipolar disorder: relation to clinical state, cognitive performance, medication status, and substance disorders.
     Bipolar Disord, 12(8): 793-803. [Abstract] [Full-text]
254. Family-based association analysis to finemap bipolar linkage peak on chromosome 8q24 using 2,500 genotyped SNPs and 15,000 imputed SNPs.
     Bipolar Disord, 12(8): 786-92. [Abstract] [Full-text]
255. Striatal structure and function in mood disorders: a comprehensive review.
     Bipolar Disord, 12(8): 764-85. [Abstract] [Full-text]
256. Utilization of residential alcoholism treatment in bipolar disorder.
     Am J Addict, 20(1): 40-4. [Abstract] [Full-text]
257. Impact of psychiatric comorbidity on mortality in veterans with type 2 diabetes.
     Diabetes Technol Ther, 13(1): 73-8. [Abstract] [Full-text]
258. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries.
     Hum Mol Genet, 20(2): 387-91. [Abstract] [Full-text]
259. Expanding the range of ZNF804A variants conferring risk of psychosis.
     Mol Psychiatry, 16(1): 59-66. [Abstract] [Full-text]
260. Utilization of residential alcoholism treatment in bipolar disorder.
     Am J Addict, 20(1): 40-4. [Abstract] [Full-text]
261. Impact of psychiatric comorbidity on mortality in veterans with type 2 diabetes.
     Diabetes Technol Ther, 13(1): 73-8. [Abstract] [Full-text]
262. Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes.
     Psychiatr Genet, 21(1): 1-4. [Abstract] [Full-text]
263. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries.
     Hum Mol Genet, 20(2): 387-91. [Abstract] [Full-text]
264. Expanding the range of ZNF804A variants conferring risk of psychosis.
     Mol Psychiatry, 16(1): 59-66. [Abstract] [Full-text]
265. Utilization of residential alcoholism treatment in bipolar disorder.
     Am J Addict, 20(1): 40-4. [Abstract] [Full-text]
266. Impact of psychiatric comorbidity on mortality in veterans with type 2 diabetes.
     Diabetes Technol Ther, 13(1): 73-8. [Abstract] [Full-text]
267. Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes.
     Psychiatr Genet, 21(1): 1-4. [Abstract] [Full-text]
268. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries.
     Hum Mol Genet, 20(2): 387-91. [Abstract] [Full-text]
269. Expanding the range of ZNF804A variants conferring risk of psychosis.
     Mol Psychiatry, 16(1): 59-66. [Abstract] [Full-text]
270. No Association of the YWHAE Gene with Schizophrenia, Major Depressive Disorder or Bipolar Disorder in the Han Chinese Population.
     Behav Genet. [Abstract] [Full-text]
271. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival.
     Proteomics, 11(1): 94-105. [Abstract] [Full-text]
272. Fine mapping of candidate regions for bipolar disorder provides strong evidence for susceptibility loci on chromosomes 7q.
     Am J Med Genet B Neuropsychiatr Genet. [Abstract] [Full-text]
273. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival.
     Proteomics, 11(1): 94-105. [Abstract] [Full-text]
274. No Association of the YWHAE Gene with Schizophrenia, Major Depressive Disorder or Bipolar Disorder in the Han Chinese Population.
     Behav Genet. [Abstract] [Full-text]
275. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder.
     Biol Psychiatry, 69(2): 188-93. [Abstract] [Full-text]
276. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival.
     Proteomics, 11(1): 94-105. [Abstract] [Full-text]
277. Fine mapping of candidate regions for bipolar disorder provides strong evidence for susceptibility loci on chromosomes 7q.
     Am J Med Genet B Neuropsychiatr Genet. [Abstract] [Full-text]
278. The neuroproteomics of schizophrenia.
     Biol Psychiatry, 69(2): 163-72. [Abstract] [Full-text]
279. Epigenetic studies of psychosis: current findings, methodological approaches, and implications for postmortem research.
     Biol Psychiatry, 69(2): 146-56. [Abstract] [Full-text]
280. No Association of the YWHAE Gene with Schizophrenia, Major Depressive Disorder or Bipolar Disorder in the Han Chinese Population.
     Behav Genet. [Abstract] [Full-text]
281. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder.
     Biol Psychiatry, 69(2): 188-93. [Abstract] [Full-text]
282. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival.
     Proteomics, 11(1): 94-105. [Abstract] [Full-text]
283. Fine mapping of candidate regions for bipolar disorder provides strong evidence for susceptibility loci on chromosomes 7q.
     Am J Med Genet B Neuropsychiatr Genet. [Abstract] [Full-text]
284. The neuroproteomics of schizophrenia.
     Biol Psychiatry, 69(2): 163-72. [Abstract] [Full-text]
285. Epigenetic studies of psychosis: current findings, methodological approaches, and implications for postmortem research.
     Biol Psychiatry, 69(2): 146-56. [Abstract] [Full-text]
286. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder.
     Biol Psychiatry, 69(2): 188-93. [Abstract] [Full-text]
287. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival.
     Proteomics, 11(1): 94-105. [Abstract] [Full-text]
288. The neuroproteomics of schizophrenia.
     Biol Psychiatry, 69(2): 163-72. [Abstract] [Full-text]
289. Epigenetic studies of psychosis: current findings, methodological approaches, and implications for postmortem research.
     Biol Psychiatry, 69(2): 146-56. [Abstract] [Full-text]
290. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability?
     Brain Behav Immun. [Abstract] [Full-text]
291. Histone Deacetylases in Skeletal Development and Bone Mass Maintenance.
     Gene. [Abstract] [Full-text]
292. Screening for postpartum bipolar disorder: Validation of the Mood Disorder Questionnaire.
     J Affect Disord. [Abstract] [Full-text]
293. Gene Expression and Genetic Variation Data Implicate PCLO in Bipolar Disorder.
     Biol Psychiatry. [Abstract] [Full-text]
294. Valproate uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: Relevance to valproate's efficacy against bipolar disorder.
     Biochim Biophys Acta. [Abstract] [Full-text]
295. Regulation of cell cycle and DNA repair in post-mitotic GABA neurons in psychotic disorders.
     Neuropharmacology. [Abstract] [Full-text]
296. Excess mortality associated with mental illness and substance use disorders among veteran clinic users with spinal cord injury.
     Disabil Rehabil. [Abstract] [Full-text]
297. Increased breath ethane levels in medicated patients with schizophrenia and bipolar disorder are unrelated to erythrocyte omega-3 fatty acid abundance.
     Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
298. Phosphatidylinositol 3-Kinase (PI3K) Signaling via Glycogen Synthase Kinase-3 (Gsk-3) Regulates DNA Methylation of Imprinted Loci.
     J Biol Chem, 285(53): 41337-47. [Abstract] [Full-text]
299. Screening for postpartum bipolar disorder: Validation of the Mood Disorder Questionnaire.
     J Affect Disord. [Abstract] [Full-text]
300. Gene Expression and Genetic Variation Data Implicate PCLO in Bipolar Disorder.
     Biol Psychiatry. [Abstract] [Full-text]
301. Excess mortality associated with mental illness and substance use disorders among veteran clinic users with spinal cord injury.
     Disabil Rehabil. [Abstract] [Full-text]
302. Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci.
     J Biol Chem, 285(53): 41337-47. [Abstract] [Full-text]
303. Screening for postpartum bipolar disorder: Validation of the Mood Disorder Questionnaire.
     J Affect Disord. [Abstract] [Full-text]
304. Excess mortality associated with mental illness and substance use disorders among veteran clinic users with spinal cord injury.
     Disabil Rehabil. [Abstract] [Full-text]
305. Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci.
     J Biol Chem, 285(53): 41337-47. [Abstract] [Full-text]
306. Different gray matter patterns in chronic schizophrenia and chronic bipolar disorder patients identified using voxel-based morphometry.
     Eur Arch Psychiatry Clin Neurosci. [Abstract] [Full-text]
307. Different gray matter patterns in chronic schizophrenia and chronic bipolar disorder patients identified using voxel-based morphometry.
     Eur Arch Psychiatry Clin Neurosci. [Abstract] [Full-text]
308. Different gray matter patterns in chronic schizophrenia and chronic bipolar disorder patients identified using voxel-based morphometry.
     Eur Arch Psychiatry Clin Neurosci. [Abstract] [Full-text]
309. Activation of suicidal ideation with adjunctive rufinamide in bipolar disorder.
     Epilepsy Behav. [Abstract] [Full-text]
310. Activation of suicidal ideation with adjunctive rufinamide in bipolar disorder.
     Epilepsy Behav. [Abstract] [Full-text]
311. Activation of suicidal ideation with adjunctive rufinamide in bipolar disorder.
     Epilepsy Behav. [Abstract] [Full-text]
312. Genetic association of bipolar disorder with the β3 nicotinic receptor subunit gene.
     Psychiatr Genet. [Abstract] [Full-text]
313. Bipolar disorder: new perspectives in health care and prevention.
     J Clin Psychiatry, 71(12): 1689-95. [Abstract] [Full-text]
314. Approaches to preventing relapse in bipolar disorder: addressing nonadherence and prodromal symptoms.
     J Clin Psychiatry, 71(12): e35. [Abstract] [Full-text]
315. Common promoter variants of the NDUFV2 gene do not confer susceptibility to schizophrenia in Han Chinese.
     Behav Brain Funct, 6(1): 75. [Abstract] [Full-text]
316. Characteristics of children with elevated symptoms of mania: the Longitudinal Assessment of Manic Symptoms (LAMS) study.
     J Clin Psychiatry, 71(12): 1664-72. [Abstract] [Full-text]
317. Genetic association of bipolar disorder with the β3 nicotinic receptor subunit gene.
     Psychiatr Genet. [Abstract] [Full-text]
318. Bipolar disorder: new perspectives in health care and prevention.
     J Clin Psychiatry, 71(12): 1689-95. [Abstract] [Full-text]
319. Approaches to preventing relapse in bipolar disorder: addressing nonadherence and prodromal symptoms.
     J Clin Psychiatry, 71(12): e35. [Abstract] [Full-text]
320. Common promoter variants of the NDUFV2 gene do not confer susceptibility to schizophrenia in Han Chinese.
     Behav Brain Funct, 6(1): 75. [Abstract] [Full-text]
321. Characteristics of children with elevated symptoms of mania: the Longitudinal Assessment of Manic Symptoms (LAMS) study.
     J Clin Psychiatry, 71(12): 1664-72. [Abstract] [Full-text]
322. Genetic association of bipolar disorder with the β3 nicotinic receptor subunit gene.
     Psychiatr Genet. [Abstract] [Full-text]
323. Staging bipolar disorder.
     Neurotox Res, 19(2): 279-85. [Abstract] [Full-text]
324. Staging bipolar disorder.
     Neurotox Res, 19(2): 279-85. [Abstract] [Full-text]

© 2004-2013 Bipolar Research Today. All Rights Reserved.